A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/7/669 |
| _version_ | 1797528491208474624 |
|---|---|
| author | Mariana Cornelia Tilinca Robert Aurelian Tiuca Alexandru Burlacu Andreea Varga |
| author_facet | Mariana Cornelia Tilinca Robert Aurelian Tiuca Alexandru Burlacu Andreea Varga |
| author_sort | Mariana Cornelia Tilinca |
| collection | DOAJ |
| description | Obesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes. |
| first_indexed | 2024-03-10T09:59:04Z |
| format | Article |
| id | doaj.art-d715b023cedd4d7fa67d2c4edc24dd38 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T09:59:04Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-d715b023cedd4d7fa67d2c4edc24dd382023-11-22T02:07:31ZengMDPI AGMedicina1010-660X1648-91442021-06-0157766910.3390/medicina57070669A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative ReviewMariana Cornelia Tilinca0Robert Aurelian Tiuca1Alexandru Burlacu2Andreea Varga3Discipline of Internal Medicine, Department ME2, Faculty of Medicine, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology, 540142 Targu Mures, RomaniaClinic of Endocrinology, Mures County Clinical Hospital, 540072 Targu Mures, RomaniaFaculty of Medicine, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment ME2, Faculty of Medicine, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology, 540136 Targu Mures, RomaniaObesity and type 2 diabetes mellitus have become a significant public health problem in the past decades. Their prevalence is increasing worldwide each year, greatly impacting the economic and personal aspects, mainly because they frequently coexist, where the term “diabesity” may be used. The drug class of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is one of the most modern therapy options in managing these metabolic disorders. This review focuses on the effects of liraglutide, a long-acting GLP-1 RA, in diabesity and non-diabetic excess weight. This drug class improves glycemic control by enhancing insulin secretion from the beta-pancreatic cells and inhibiting glucagon release. Furthermore, other effects include slowing gastric emptying, increasing postprandial satiety, and reducing the appetite and food consumption by influencing the central nervous system, with weight reduction effects. It also reduces cardiovascular events and has positive effects on blood pressure and lipid profile. A lower-dose liraglutide (1.2 or 1.8 mg/day) is used in patients with diabetes, while the higher dose (3.0 mg/day) is approved as an anti-obesity drug. In this review, we have summarized the role of liraglutide in clinical practice, highlighting its safety and efficacy as a glucose-lowering agent and a weight-reduction drug in patients with and without diabetes.https://www.mdpi.com/1648-9144/57/7/669type 2 diabetesobesityGLP-1 RAsliraglutidediabesity |
| spellingShingle | Mariana Cornelia Tilinca Robert Aurelian Tiuca Alexandru Burlacu Andreea Varga A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review Medicina type 2 diabetes obesity GLP-1 RAs liraglutide diabesity |
| title | A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review |
| title_full | A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review |
| title_fullStr | A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review |
| title_full_unstemmed | A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review |
| title_short | A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review |
| title_sort | 2021 update on the use of liraglutide in the modern treatment of diabesity a narrative review |
| topic | type 2 diabetes obesity GLP-1 RAs liraglutide diabesity |
| url | https://www.mdpi.com/1648-9144/57/7/669 |
| work_keys_str_mv | AT marianacorneliatilinca a2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT robertaureliantiuca a2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT alexandruburlacu a2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT andreeavarga a2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT marianacorneliatilinca 2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT robertaureliantiuca 2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT alexandruburlacu 2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview AT andreeavarga 2021updateontheuseofliraglutideinthemoderntreatmentofdiabesityanarrativereview |